The downgrade from Buy to Hold and the drastic reduction in price target from $22 to $3 by Stifel suggests a significant loss of confidence in Fulcrum Therapeutics' short-term prospects. This is likely to negatively impact the stock price as investors react to the analyst's revised outlook.